nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADA—prostate gland—prostate cancer	0.0138	0.0943	CbGeAlD
Vidarabine—ADK—prostate gland—prostate cancer	0.0113	0.077	CbGeAlD
Vidarabine—DPP4—prostate gland—prostate cancer	0.0109	0.0747	CbGeAlD
Vidarabine—ADK—seminal vesicle—prostate cancer	0.00953	0.0652	CbGeAlD
Vidarabine—ADA—renal system—prostate cancer	0.0094	0.0643	CbGeAlD
Vidarabine—DPP4—seminal vesicle—prostate cancer	0.00924	0.0632	CbGeAlD
Vidarabine—DPP4—epithelium—prostate cancer	0.00803	0.0549	CbGeAlD
Vidarabine—ADK—renal system—prostate cancer	0.00768	0.0525	CbGeAlD
Vidarabine—ADK—urethra—prostate cancer	0.00755	0.0516	CbGeAlD
Vidarabine—DPP4—renal system—prostate cancer	0.00745	0.0509	CbGeAlD
Vidarabine—ADA—bone marrow—prostate cancer	0.00711	0.0486	CbGeAlD
Vidarabine—ADA—testis—prostate cancer	0.00608	0.0415	CbGeAlD
Vidarabine—ADK—bone marrow—prostate cancer	0.00581	0.0397	CbGeAlD
Vidarabine—DPP4—bone marrow—prostate cancer	0.00563	0.0385	CbGeAlD
Vidarabine—ADORA2A—testis—prostate cancer	0.00553	0.0378	CbGeAlD
Vidarabine—ADK—testis—prostate cancer	0.00496	0.0339	CbGeAlD
Vidarabine—DPP4—testis—prostate cancer	0.00481	0.0329	CbGeAlD
Vidarabine—ADA—lymph node—prostate cancer	0.0044	0.0301	CbGeAlD
Vidarabine—S-Adenosylmethionine—GNMT—prostate cancer	0.00381	0.201	CrCbGaD
Vidarabine—ADK—lymph node—prostate cancer	0.0036	0.0246	CbGeAlD
Vidarabine—DPP4—lymph node—prostate cancer	0.00349	0.0239	CbGeAlD
Vidarabine—Azacitidine—DNMT1—prostate cancer	0.00242	0.128	CrCbGaD
Vidarabine—Decitabine—DNMT1—prostate cancer	0.00236	0.125	CrCbGaD
Vidarabine—Adenosine triphosphate—HSPA1A—prostate cancer	0.00215	0.114	CrCbGaD
Vidarabine—Glucosamine—MMP9—prostate cancer	0.00131	0.0694	CrCbGaD
Vidarabine—S-Adenosylmethionine—COMT—prostate cancer	0.000976	0.0517	CrCbGaD
Vidarabine—Adenosine monophosphate—PDE4D—prostate cancer	0.00095	0.0503	CrCbGaD
Vidarabine—Adenosine triphosphate—AKT1—prostate cancer	0.000843	0.0446	CrCbGaD
Vidarabine—Adenosine monophosphate—SRC—prostate cancer	0.000831	0.044	CrCbGaD
Vidarabine—Glucosamine—CYP2E1—prostate cancer	0.000663	0.0351	CrCbGaD
Vidarabine—Glucosamine—CYP2C19—prostate cancer	0.000657	0.0348	CrCbGaD
Vidarabine—Cytarabine—SLC22A1—prostate cancer	0.000647	0.0342	CrCbGaD
Vidarabine—Cladribine—SLC22A1—prostate cancer	0.000595	0.0315	CrCbGaD
Vidarabine—S-Adenosylmethionine—CYP2E1—prostate cancer	0.000454	0.0241	CrCbGaD
Vidarabine—Acute coronary syndrome—Prednisone—prostate cancer	0.000404	0.000716	CcSEcCtD
Vidarabine—Pain—Estradiol—prostate cancer	0.000403	0.000713	CcSEcCtD
Vidarabine—Myocardial infarction—Prednisone—prostate cancer	0.000402	0.000712	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.0004	0.000708	CcSEcCtD
Vidarabine—Flushing—Docetaxel—prostate cancer	0.000396	0.000702	CcSEcCtD
Vidarabine—Cardiac disorder—Docetaxel—prostate cancer	0.000396	0.000702	CcSEcCtD
Vidarabine—Cardiac arrest—Epirubicin—prostate cancer	0.000396	0.000701	CcSEcCtD
Vidarabine—Cardiac failure—Doxorubicin—prostate cancer	0.000395	0.000699	CcSEcCtD
Vidarabine—Mood swings—Epirubicin—prostate cancer	0.000394	0.000699	CcSEcCtD
Vidarabine—Paraesthesia—Mitoxantrone—prostate cancer	0.000394	0.000698	CcSEcCtD
Vidarabine—Loss of consciousness—Etoposide—prostate cancer	0.000393	0.000696	CcSEcCtD
Vidarabine—Cerebrovascular accident—Doxorubicin—prostate cancer	0.000393	0.000696	CcSEcCtD
Vidarabine—Dizziness—Goserelin—prostate cancer	0.000393	0.000696	CcSEcCtD
Vidarabine—Dyspnoea—Mitoxantrone—prostate cancer	0.000391	0.000693	CcSEcCtD
Vidarabine—Cough—Etoposide—prostate cancer	0.00039	0.000691	CcSEcCtD
Vidarabine—Somnolence—Mitoxantrone—prostate cancer	0.00039	0.000691	CcSEcCtD
Vidarabine—Dizziness—Conjugated Estrogens—prostate cancer	0.000389	0.000689	CcSEcCtD
Vidarabine—Convulsion—Etoposide—prostate cancer	0.000388	0.000686	CcSEcCtD
Vidarabine—Hypertension—Etoposide—prostate cancer	0.000386	0.000684	CcSEcCtD
Vidarabine—Tinnitus—Capecitabine—prostate cancer	0.000385	0.000683	CcSEcCtD
Vidarabine—Mediastinal disorder—Docetaxel—prostate cancer	0.000385	0.000682	CcSEcCtD
Vidarabine—Cardiac disorder—Capecitabine—prostate cancer	0.000384	0.00068	CcSEcCtD
Vidarabine—Flushing—Capecitabine—prostate cancer	0.000384	0.00068	CcSEcCtD
Vidarabine—Arrhythmia—Docetaxel—prostate cancer	0.000381	0.000676	CcSEcCtD
Vidarabine—Chest pain—Etoposide—prostate cancer	0.000381	0.000675	CcSEcCtD
Vidarabine—Affect lability—Doxorubicin—prostate cancer	0.000379	0.000672	CcSEcCtD
Vidarabine—Vomiting—Goserelin—prostate cancer	0.000378	0.000669	CcSEcCtD
Vidarabine—Discomfort—Etoposide—prostate cancer	0.000376	0.000666	CcSEcCtD
Vidarabine—Pain—Mitoxantrone—prostate cancer	0.000375	0.000665	CcSEcCtD
Vidarabine—Bradycardia—Prednisone—prostate cancer	0.000375	0.000664	CcSEcCtD
Vidarabine—Rash—Goserelin—prostate cancer	0.000375	0.000664	CcSEcCtD
Vidarabine—Dermatitis—Goserelin—prostate cancer	0.000374	0.000663	CcSEcCtD
Vidarabine—Vomiting—Conjugated Estrogens—prostate cancer	0.000374	0.000663	CcSEcCtD
Vidarabine—Urticaria—Estradiol—prostate cancer	0.000374	0.000663	CcSEcCtD
Vidarabine—Mediastinal disorder—Capecitabine—prostate cancer	0.000373	0.00066	CcSEcCtD
Vidarabine—Headache—Goserelin—prostate cancer	0.000372	0.000659	CcSEcCtD
Vidarabine—Rash—Conjugated Estrogens—prostate cancer	0.000371	0.000657	CcSEcCtD
Vidarabine—Dermatitis—Conjugated Estrogens—prostate cancer	0.000371	0.000657	CcSEcCtD
Vidarabine—Arrhythmia—Capecitabine—prostate cancer	0.000369	0.000654	CcSEcCtD
Vidarabine—Headache—Conjugated Estrogens—prostate cancer	0.000369	0.000653	CcSEcCtD
Vidarabine—Cardiac arrest—Doxorubicin—prostate cancer	0.000366	0.000649	CcSEcCtD
Vidarabine—Anaphylactic shock—Etoposide—prostate cancer	0.000365	0.000647	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—prostate cancer	0.000365	0.000646	CcSEcCtD
Vidarabine—Dysgeusia—Docetaxel—prostate cancer	0.000364	0.000645	CcSEcCtD
Vidarabine—Back pain—Docetaxel—prostate cancer	0.00036	0.000637	CcSEcCtD
Vidarabine—Tachycardia—Etoposide—prostate cancer	0.000356	0.000631	CcSEcCtD
Vidarabine—Nausea—Goserelin—prostate cancer	0.000353	0.000625	CcSEcCtD
Vidarabine—Hyperhidrosis—Etoposide—prostate cancer	0.000353	0.000625	CcSEcCtD
Vidarabine—Dysgeusia—Capecitabine—prostate cancer	0.000352	0.000624	CcSEcCtD
Vidarabine—Nausea—Conjugated Estrogens—prostate cancer	0.00035	0.000619	CcSEcCtD
Vidarabine—Urticaria—Mitoxantrone—prostate cancer	0.000349	0.000618	CcSEcCtD
Vidarabine—Back pain—Capecitabine—prostate cancer	0.000348	0.000617	CcSEcCtD
Vidarabine—Hypersensitivity—Estradiol—prostate cancer	0.000347	0.000615	CcSEcCtD
Vidarabine—Flushing—Prednisone—prostate cancer	0.000342	0.000605	CcSEcCtD
Vidarabine—Hypotension—Etoposide—prostate cancer	0.000341	0.000604	CcSEcCtD
Vidarabine—Vision blurred—Capecitabine—prostate cancer	0.000339	0.000601	CcSEcCtD
Vidarabine—Asthenia—Estradiol—prostate cancer	0.000338	0.000599	CcSEcCtD
Vidarabine—Tremor—Capecitabine—prostate cancer	0.000337	0.000597	CcSEcCtD
Vidarabine—Syncope—Docetaxel—prostate cancer	0.000333	0.00059	CcSEcCtD
Vidarabine—Pollakiuria—Epirubicin—prostate cancer	0.000332	0.000589	CcSEcCtD
Vidarabine—Arrhythmia—Prednisone—prostate cancer	0.000329	0.000583	CcSEcCtD
Vidarabine—Palpitations—Docetaxel—prostate cancer	0.000328	0.000582	CcSEcCtD
Vidarabine—Paraesthesia—Etoposide—prostate cancer	0.000328	0.000581	CcSEcCtD
Vidarabine—Loss of consciousness—Docetaxel—prostate cancer	0.000327	0.000579	CcSEcCtD
Vidarabine—Dyspnoea—Etoposide—prostate cancer	0.000325	0.000577	CcSEcCtD
Vidarabine—Somnolence—Etoposide—prostate cancer	0.000325	0.000575	CcSEcCtD
Vidarabine—Cough—Docetaxel—prostate cancer	0.000324	0.000575	CcSEcCtD
Vidarabine—Hypersensitivity—Mitoxantrone—prostate cancer	0.000323	0.000573	CcSEcCtD
Vidarabine—Syncope—Capecitabine—prostate cancer	0.000323	0.000572	CcSEcCtD
Vidarabine—Convulsion—Docetaxel—prostate cancer	0.000322	0.000571	CcSEcCtD
Vidarabine—Hypertension—Docetaxel—prostate cancer	0.000321	0.000568	CcSEcCtD
Vidarabine—Drowsiness—Epirubicin—prostate cancer	0.000321	0.000568	CcSEcCtD
Vidarabine—Palpitations—Capecitabine—prostate cancer	0.000318	0.000563	CcSEcCtD
Vidarabine—Chest pain—Docetaxel—prostate cancer	0.000316	0.000561	CcSEcCtD
Vidarabine—Loss of consciousness—Capecitabine—prostate cancer	0.000316	0.00056	CcSEcCtD
Vidarabine—Asthenia—Mitoxantrone—prostate cancer	0.000315	0.000558	CcSEcCtD
Vidarabine—Cough—Capecitabine—prostate cancer	0.000314	0.000556	CcSEcCtD
Vidarabine—Pain—Etoposide—prostate cancer	0.000312	0.000553	CcSEcCtD
Vidarabine—Dizziness—Estradiol—prostate cancer	0.000311	0.000552	CcSEcCtD
Vidarabine—Hypertension—Capecitabine—prostate cancer	0.000311	0.00055	CcSEcCtD
Vidarabine—Dry mouth—Docetaxel—prostate cancer	0.00031	0.000548	CcSEcCtD
Vidarabine—Sweating—Epirubicin—prostate cancer	0.000308	0.000545	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—prostate cancer	0.000308	0.000545	CcSEcCtD
Vidarabine—Chest pain—Capecitabine—prostate cancer	0.000306	0.000543	CcSEcCtD
Vidarabine—Anxiety—Capecitabine—prostate cancer	0.000305	0.000541	CcSEcCtD
Vidarabine—Anaphylactic shock—Docetaxel—prostate cancer	0.000303	0.000537	CcSEcCtD
Vidarabine—Discomfort—Capecitabine—prostate cancer	0.000303	0.000536	CcSEcCtD
Vidarabine—Vision blurred—Prednisone—prostate cancer	0.000302	0.000535	CcSEcCtD
Vidarabine—Dry mouth—Capecitabine—prostate cancer	0.0003	0.000531	CcSEcCtD
Vidarabine—Vomiting—Estradiol—prostate cancer	0.000299	0.00053	CcSEcCtD
Vidarabine—Shock—Docetaxel—prostate cancer	0.000298	0.000529	CcSEcCtD
Vidarabine—Rash—Estradiol—prostate cancer	0.000297	0.000526	CcSEcCtD
Vidarabine—Drowsiness—Doxorubicin—prostate cancer	0.000297	0.000526	CcSEcCtD
Vidarabine—Dermatitis—Estradiol—prostate cancer	0.000297	0.000526	CcSEcCtD
Vidarabine—Tachycardia—Docetaxel—prostate cancer	0.000296	0.000524	CcSEcCtD
Vidarabine—Headache—Estradiol—prostate cancer	0.000295	0.000523	CcSEcCtD
Vidarabine—Agitation—Prednisone—prostate cancer	0.000295	0.000522	CcSEcCtD
Vidarabine—Bradycardia—Epirubicin—prostate cancer	0.000293	0.000519	CcSEcCtD
Vidarabine—Angioedema—Prednisone—prostate cancer	0.000293	0.000519	CcSEcCtD
Vidarabine—Urticaria—Etoposide—prostate cancer	0.00029	0.000514	CcSEcCtD
Vidarabine—Shock—Capecitabine—prostate cancer	0.000289	0.000512	CcSEcCtD
Vidarabine—Syncope—Prednisone—prostate cancer	0.000287	0.000509	CcSEcCtD
Vidarabine—Tachycardia—Capecitabine—prostate cancer	0.000287	0.000508	CcSEcCtD
Vidarabine—Hypoaesthesia—Epirubicin—prostate cancer	0.000287	0.000508	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—prostate cancer	0.000285	0.000504	CcSEcCtD
Vidarabine—Hyperhidrosis—Capecitabine—prostate cancer	0.000284	0.000503	CcSEcCtD
Vidarabine—Hypotension—Docetaxel—prostate cancer	0.000283	0.000502	CcSEcCtD
Vidarabine—Loss of consciousness—Prednisone—prostate cancer	0.000282	0.000499	CcSEcCtD
Vidarabine—Nausea—Estradiol—prostate cancer	0.00028	0.000496	CcSEcCtD
Vidarabine—Vomiting—Mitoxantrone—prostate cancer	0.000279	0.000494	CcSEcCtD
Vidarabine—Convulsion—Prednisone—prostate cancer	0.000278	0.000492	CcSEcCtD
Vidarabine—Hypertension—Prednisone—prostate cancer	0.000277	0.00049	CcSEcCtD
Vidarabine—Rash—Mitoxantrone—prostate cancer	0.000277	0.00049	CcSEcCtD
Vidarabine—Dermatitis—Mitoxantrone—prostate cancer	0.000276	0.00049	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000276	0.00049	CcSEcCtD
Vidarabine—Headache—Mitoxantrone—prostate cancer	0.000275	0.000487	CcSEcCtD
Vidarabine—Hypotension—Capecitabine—prostate cancer	0.000274	0.000486	CcSEcCtD
Vidarabine—Paraesthesia—Docetaxel—prostate cancer	0.000272	0.000483	CcSEcCtD
Vidarabine—Anxiety—Prednisone—prostate cancer	0.000272	0.000482	CcSEcCtD
Vidarabine—Bradycardia—Doxorubicin—prostate cancer	0.000271	0.000481	CcSEcCtD
Vidarabine—Dyspnoea—Docetaxel—prostate cancer	0.00027	0.000479	CcSEcCtD
Vidarabine—Somnolence—Docetaxel—prostate cancer	0.00027	0.000478	CcSEcCtD
Vidarabine—Discomfort—Prednisone—prostate cancer	0.00027	0.000478	CcSEcCtD
Vidarabine—Hypersensitivity—Etoposide—prostate cancer	0.000269	0.000476	CcSEcCtD
Vidarabine—Tinnitus—Epirubicin—prostate cancer	0.000269	0.000476	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000268	0.000474	CcSEcCtD
Vidarabine—Cardiac disorder—Epirubicin—prostate cancer	0.000267	0.000474	CcSEcCtD
Vidarabine—Flushing—Epirubicin—prostate cancer	0.000267	0.000474	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—prostate cancer	0.000265	0.00047	CcSEcCtD
Vidarabine—Paraesthesia—Capecitabine—prostate cancer	0.000264	0.000467	CcSEcCtD
Vidarabine—Asthenia—Etoposide—prostate cancer	0.000262	0.000464	CcSEcCtD
Vidarabine—Dyspnoea—Capecitabine—prostate cancer	0.000262	0.000464	CcSEcCtD
Vidarabine—Anaphylactic shock—Prednisone—prostate cancer	0.000262	0.000463	CcSEcCtD
Vidarabine—Nausea—Mitoxantrone—prostate cancer	0.000261	0.000462	CcSEcCtD
Vidarabine—Mediastinal disorder—Epirubicin—prostate cancer	0.00026	0.00046	CcSEcCtD
Vidarabine—Pain—Docetaxel—prostate cancer	0.000259	0.00046	CcSEcCtD
Vidarabine—Shock—Prednisone—prostate cancer	0.000257	0.000456	CcSEcCtD
Vidarabine—Arrhythmia—Epirubicin—prostate cancer	0.000257	0.000456	CcSEcCtD
Vidarabine—Tachycardia—Prednisone—prostate cancer	0.000255	0.000452	CcSEcCtD
Vidarabine—Hyperhidrosis—Prednisone—prostate cancer	0.000253	0.000448	CcSEcCtD
Vidarabine—Pain—Capecitabine—prostate cancer	0.000251	0.000445	CcSEcCtD
Vidarabine—Tinnitus—Doxorubicin—prostate cancer	0.000248	0.00044	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—prostate cancer	0.000247	0.000438	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—prostate cancer	0.000247	0.000438	CcSEcCtD
Vidarabine—Tension—Epirubicin—prostate cancer	0.000246	0.000436	CcSEcCtD
Vidarabine—Dysgeusia—Epirubicin—prostate cancer	0.000246	0.000435	CcSEcCtD
Vidarabine—Nervousness—Epirubicin—prostate cancer	0.000244	0.000431	CcSEcCtD
Vidarabine—Back pain—Epirubicin—prostate cancer	0.000243	0.00043	CcSEcCtD
Vidarabine—Dizziness—Etoposide—prostate cancer	0.000241	0.000428	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—prostate cancer	0.00024	0.000425	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000238	0.000422	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—prostate cancer	0.000238	0.000422	CcSEcCtD
Vidarabine—Vision blurred—Epirubicin—prostate cancer	0.000236	0.000419	CcSEcCtD
Vidarabine—Paraesthesia—Prednisone—prostate cancer	0.000235	0.000416	CcSEcCtD
Vidarabine—Urticaria—Capecitabine—prostate cancer	0.000233	0.000413	CcSEcCtD
Vidarabine—Vomiting—Etoposide—prostate cancer	0.000232	0.000411	CcSEcCtD
Vidarabine—Agitation—Epirubicin—prostate cancer	0.00023	0.000408	CcSEcCtD
Vidarabine—Rash—Etoposide—prostate cancer	0.00023	0.000408	CcSEcCtD
Vidarabine—Dermatitis—Etoposide—prostate cancer	0.00023	0.000407	CcSEcCtD
Vidarabine—Headache—Etoposide—prostate cancer	0.000229	0.000405	CcSEcCtD
Vidarabine—Tension—Doxorubicin—prostate cancer	0.000228	0.000403	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—prostate cancer	0.000227	0.000402	CcSEcCtD
Vidarabine—Cytarabine—CYP3A4—prostate cancer	0.000226	0.012	CrCbGaD
Vidarabine—Nervousness—Doxorubicin—prostate cancer	0.000225	0.000399	CcSEcCtD
Vidarabine—Syncope—Epirubicin—prostate cancer	0.000225	0.000398	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—prostate cancer	0.000224	0.000398	CcSEcCtD
Vidarabine—Hypersensitivity—Docetaxel—prostate cancer	0.000224	0.000396	CcSEcCtD
Vidarabine—Palpitations—Epirubicin—prostate cancer	0.000222	0.000392	CcSEcCtD
Vidarabine—Loss of consciousness—Epirubicin—prostate cancer	0.00022	0.00039	CcSEcCtD
Vidarabine—Cough—Epirubicin—prostate cancer	0.000219	0.000388	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—prostate cancer	0.000219	0.000387	CcSEcCtD
Vidarabine—Asthenia—Docetaxel—prostate cancer	0.000218	0.000386	CcSEcCtD
Vidarabine—Convulsion—Epirubicin—prostate cancer	0.000217	0.000385	CcSEcCtD
Vidarabine—Nausea—Etoposide—prostate cancer	0.000217	0.000384	CcSEcCtD
Vidarabine—Hypertension—Epirubicin—prostate cancer	0.000216	0.000383	CcSEcCtD
Vidarabine—Hypersensitivity—Capecitabine—prostate cancer	0.000216	0.000383	CcSEcCtD
Vidarabine—Chest pain—Epirubicin—prostate cancer	0.000213	0.000378	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—prostate cancer	0.000213	0.000378	CcSEcCtD
Vidarabine—Anxiety—Epirubicin—prostate cancer	0.000213	0.000377	CcSEcCtD
Vidarabine—Discomfort—Epirubicin—prostate cancer	0.000211	0.000374	CcSEcCtD
Vidarabine—Asthenia—Capecitabine—prostate cancer	0.000211	0.000373	CcSEcCtD
Vidarabine—Dry mouth—Epirubicin—prostate cancer	0.000209	0.00037	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—prostate cancer	0.000208	0.000369	CcSEcCtD
Vidarabine—Urticaria—Prednisone—prostate cancer	0.000208	0.000368	CcSEcCtD
Vidarabine—Palpitations—Doxorubicin—prostate cancer	0.000205	0.000363	CcSEcCtD
Vidarabine—Anaphylactic shock—Epirubicin—prostate cancer	0.000205	0.000362	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—prostate cancer	0.000204	0.000361	CcSEcCtD
Vidarabine—Cough—Doxorubicin—prostate cancer	0.000202	0.000359	CcSEcCtD
Vidarabine—Shock—Epirubicin—prostate cancer	0.000201	0.000357	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—prostate cancer	0.000201	0.000356	CcSEcCtD
Vidarabine—Dizziness—Docetaxel—prostate cancer	0.000201	0.000355	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—prostate cancer	0.0002	0.000355	CcSEcCtD
Vidarabine—Tachycardia—Epirubicin—prostate cancer	0.0002	0.000354	CcSEcCtD
Vidarabine—Hyperhidrosis—Epirubicin—prostate cancer	0.000198	0.00035	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—prostate cancer	0.000198	0.00035	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—prostate cancer	0.000197	0.000349	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—prostate cancer	0.000195	0.000346	CcSEcCtD
Vidarabine—Dizziness—Capecitabine—prostate cancer	0.000194	0.000344	CcSEcCtD
Vidarabine—Dry mouth—Doxorubicin—prostate cancer	0.000193	0.000342	CcSEcCtD
Vidarabine—Vomiting—Docetaxel—prostate cancer	0.000193	0.000342	CcSEcCtD
Vidarabine—Hypersensitivity—Prednisone—prostate cancer	0.000193	0.000341	CcSEcCtD
Vidarabine—Rash—Docetaxel—prostate cancer	0.000191	0.000339	CcSEcCtD
Vidarabine—Hypotension—Epirubicin—prostate cancer	0.000191	0.000339	CcSEcCtD
Vidarabine—Dermatitis—Docetaxel—prostate cancer	0.000191	0.000339	CcSEcCtD
Vidarabine—Headache—Docetaxel—prostate cancer	0.00019	0.000337	CcSEcCtD
Vidarabine—Anaphylactic shock—Doxorubicin—prostate cancer	0.000189	0.000335	CcSEcCtD
Vidarabine—Asthenia—Prednisone—prostate cancer	0.000188	0.000333	CcSEcCtD
Vidarabine—Vomiting—Capecitabine—prostate cancer	0.000187	0.000331	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000186	0.00033	CcSEcCtD
Vidarabine—Shock—Doxorubicin—prostate cancer	0.000186	0.00033	CcSEcCtD
Vidarabine—Rash—Capecitabine—prostate cancer	0.000185	0.000328	CcSEcCtD
Vidarabine—Dermatitis—Capecitabine—prostate cancer	0.000185	0.000328	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—prostate cancer	0.000185	0.000327	CcSEcCtD
Vidarabine—Headache—Capecitabine—prostate cancer	0.000184	0.000326	CcSEcCtD
Vidarabine—Paraesthesia—Epirubicin—prostate cancer	0.000184	0.000325	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—prostate cancer	0.000183	0.000324	CcSEcCtD
Vidarabine—Dyspnoea—Epirubicin—prostate cancer	0.000182	0.000323	CcSEcCtD
Vidarabine—Somnolence—Epirubicin—prostate cancer	0.000182	0.000322	CcSEcCtD
Vidarabine—Nausea—Docetaxel—prostate cancer	0.00018	0.000319	CcSEcCtD
Vidarabine—Hypotension—Doxorubicin—prostate cancer	0.000177	0.000313	CcSEcCtD
Vidarabine—Pain—Epirubicin—prostate cancer	0.000175	0.00031	CcSEcCtD
Vidarabine—Nausea—Capecitabine—prostate cancer	0.000174	0.000309	CcSEcCtD
Vidarabine—Dizziness—Prednisone—prostate cancer	0.000173	0.000306	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000173	0.000306	CcSEcCtD
Vidarabine—Paraesthesia—Doxorubicin—prostate cancer	0.00017	0.000301	CcSEcCtD
Vidarabine—Dyspnoea—Doxorubicin—prostate cancer	0.000169	0.000299	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—prostate cancer	0.000168	0.000298	CcSEcCtD
Vidarabine—Vomiting—Prednisone—prostate cancer	0.000166	0.000295	CcSEcCtD
Vidarabine—Rash—Prednisone—prostate cancer	0.000165	0.000292	CcSEcCtD
Vidarabine—Dermatitis—Prednisone—prostate cancer	0.000165	0.000292	CcSEcCtD
Vidarabine—Headache—Prednisone—prostate cancer	0.000164	0.00029	CcSEcCtD
Vidarabine—Urticaria—Epirubicin—prostate cancer	0.000163	0.000288	CcSEcCtD
Vidarabine—Pain—Doxorubicin—prostate cancer	0.000162	0.000287	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—PDE4D—prostate cancer	0.000157	0.000579	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CB—prostate cancer	0.000156	0.000578	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—VIP—prostate cancer	0.000155	0.000575	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GNRH1—prostate cancer	0.000155	0.000575	CbGpPWpGaD
Vidarabine—Nausea—Prednisone—prostate cancer	0.000155	0.000275	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—EGF—prostate cancer	0.000155	0.000573	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IRS1—prostate cancer	0.000155	0.000573	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—INS—prostate cancer	0.000154	0.000571	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PLXNB1—prostate cancer	0.000153	0.000567	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HPGDS—prostate cancer	0.000153	0.000565	CbGpPWpGaD
Vidarabine—ADK—Metabolism—COMT—prostate cancer	0.000152	0.000562	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP2C19—prostate cancer	0.000152	0.000562	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTP1—prostate cancer	0.000151	0.000559	CbGpPWpGaD
Vidarabine—Hypersensitivity—Epirubicin—prostate cancer	0.000151	0.000267	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—LPAR1—prostate cancer	0.000151	0.000557	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GRP—prostate cancer	0.000151	0.000557	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—GSK3B—prostate cancer	0.00015	0.000557	CbGpPWpGaD
Vidarabine—Urticaria—Doxorubicin—prostate cancer	0.00015	0.000266	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—IL6—prostate cancer	0.00015	0.000554	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—IGF1—prostate cancer	0.000149	0.000553	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PLCB2—prostate cancer	0.000149	0.000551	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GNG5—prostate cancer	0.000149	0.000551	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ITPR1—prostate cancer	0.000149	0.00055	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTT1—prostate cancer	0.000148	0.000548	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ACHE—prostate cancer	0.000148	0.000548	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GRPR—prostate cancer	0.000148	0.000546	CbGpPWpGaD
Vidarabine—Asthenia—Epirubicin—prostate cancer	0.000147	0.00026	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—prostate cancer	0.000147	0.000542	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP2A6—prostate cancer	0.000147	0.000542	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CX3CL1—prostate cancer	0.000146	0.000541	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—MMP2—prostate cancer	0.000145	0.000535	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKR1C3—prostate cancer	0.000143	0.000527	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL17RD—prostate cancer	0.000142	0.000527	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PDE4D—prostate cancer	0.000142	0.000526	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PRKACB—prostate cancer	0.000142	0.000525	CbGpPWpGaD
Vidarabine—ADK—Metabolism—TYMS—prostate cancer	0.000141	0.00052	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP17A1—prostate cancer	0.00014	0.000519	CbGpPWpGaD
Vidarabine—Hypersensitivity—Doxorubicin—prostate cancer	0.000139	0.000247	CcSEcCtD
Vidarabine—ADK—Metabolism—GSTM1—prostate cancer	0.000139	0.000514	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MAP2K1—prostate cancer	0.000139	0.000513	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CD—prostate cancer	0.000138	0.00051	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—PTEN—prostate cancer	0.000138	0.000509	CbGpPWpGaD
Vidarabine—ADK—Metabolism—LPL—prostate cancer	0.000136	0.000504	CbGpPWpGaD
Vidarabine—Asthenia—Doxorubicin—prostate cancer	0.000136	0.000241	CcSEcCtD
Vidarabine—Dizziness—Epirubicin—prostate cancer	0.000135	0.00024	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1A—prostate cancer	0.000135	0.0005	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GNG5—prostate cancer	0.000135	0.0005	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—prostate cancer	0.000135	0.000499	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NCOA2—prostate cancer	0.000134	0.000495	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—FGF2—prostate cancer	0.000132	0.000488	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP1A1—prostate cancer	0.000132	0.000487	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—EP300—prostate cancer	0.000131	0.000486	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ERCC2—prostate cancer	0.000131	0.000483	CbGpPWpGaD
Vidarabine—Vomiting—Epirubicin—prostate cancer	0.00013	0.00023	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—PTHLH—prostate cancer	0.00013	0.00048	CbGpPWpGaD
Vidarabine—Rash—Epirubicin—prostate cancer	0.000129	0.000229	CcSEcCtD
Vidarabine—Dermatitis—Epirubicin—prostate cancer	0.000129	0.000228	CcSEcCtD
Vidarabine—Headache—Epirubicin—prostate cancer	0.000128	0.000227	CcSEcCtD
Vidarabine—ADA—Metabolism—SLC5A5—prostate cancer	0.000128	0.000472	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—WNT4—prostate cancer	0.000127	0.00047	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JUP—prostate cancer	0.000127	0.00047	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—JAK2—prostate cancer	0.000126	0.000468	CbGpPWpGaD
Vidarabine—Dizziness—Doxorubicin—prostate cancer	0.000125	0.000222	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—prostate cancer	0.000125	0.000463	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP2E1—prostate cancer	0.000125	0.000461	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—MDM2—prostate cancer	0.000123	0.000457	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NQO1—prostate cancer	0.000123	0.000456	CbGpPWpGaD
Vidarabine—ADK—Metabolism—MTHFR—prostate cancer	0.000123	0.000454	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ANXA1—prostate cancer	0.000122	0.000451	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—ERBB2—prostate cancer	0.000122	0.00045	CbGpPWpGaD
Vidarabine—Nausea—Epirubicin—prostate cancer	0.000122	0.000215	CcSEcCtD
Vidarabine—ADA—Metabolism—TH—prostate cancer	0.000121	0.000449	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MC2R—prostate cancer	0.000121	0.000448	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RALBP1—prostate cancer	0.000121	0.000448	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—STAT3—prostate cancer	0.000121	0.000447	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PPARA—prostate cancer	0.00012	0.000446	CbGpPWpGaD
Vidarabine—Vomiting—Doxorubicin—prostate cancer	0.00012	0.000213	CcSEcCtD
Vidarabine—ADA—Metabolism—CYP3A4—prostate cancer	0.00012	0.000444	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CXCL8—prostate cancer	0.00012	0.000444	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CB—prostate cancer	0.00012	0.000444	CbGpPWpGaD
Vidarabine—Rash—Doxorubicin—prostate cancer	0.000119	0.000211	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—prostate cancer	0.000119	0.000211	CcSEcCtD
Vidarabine—Headache—Doxorubicin—prostate cancer	0.000119	0.00021	CcSEcCtD
Vidarabine—ADA—Metabolism—CYP1B1—prostate cancer	0.000118	0.000437	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PTHLH—prostate cancer	0.000118	0.000436	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PRKACB—prostate cancer	0.000115	0.000426	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GGT1—prostate cancer	0.000114	0.000423	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CALCA—prostate cancer	0.000114	0.000422	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CAV1—prostate cancer	0.000113	0.000419	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1B—prostate cancer	0.000113	0.000417	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NCOA1—prostate cancer	0.000113	0.000417	CbGpPWpGaD
Vidarabine—Nausea—Doxorubicin—prostate cancer	0.000112	0.000199	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—PPP3CA—prostate cancer	0.000112	0.000416	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL12—prostate cancer	0.000112	0.000413	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP19A1—prostate cancer	0.000111	0.000411	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CTNNB1—prostate cancer	0.000111	0.00041	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ANXA1—prostate cancer	0.000111	0.00041	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CASP3—prostate cancer	0.00011	0.000409	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—prostate cancer	0.00011	0.000406	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PENK—prostate cancer	0.000108	0.000399	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—prostate cancer	0.000107	0.000397	CbGpPWpGaD
Vidarabine—ADA—Metabolism—RXRA—prostate cancer	0.000107	0.000396	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1A—prostate cancer	0.000104	0.000385	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PTEN—prostate cancer	0.000104	0.000384	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CALCA—prostate cancer	0.000104	0.000384	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—prostate cancer	0.000104	0.000383	CbGpPWpGaD
Vidarabine—ADA—Metabolism—COMT—prostate cancer	0.000103	0.000382	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CG—prostate cancer	0.000103	0.000382	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GHR—prostate cancer	0.000103	0.000381	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTP1—prostate cancer	0.000103	0.00038	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PRKCQ—prostate cancer	0.000102	0.000377	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL12—prostate cancer	0.000101	0.000375	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ITPR1—prostate cancer	0.000101	0.000374	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NRP1—prostate cancer	9.88e-05	0.000365	CbGpPWpGaD
Vidarabine—ADK—Metabolism—INS—prostate cancer	9.76e-05	0.000361	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—SRC—prostate cancer	9.63e-05	0.000356	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ADRB2—prostate cancer	9.57e-05	0.000354	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CREBBP—prostate cancer	9.56e-05	0.000354	CbGpPWpGaD
Vidarabine—ADA—Metabolism—TYMS—prostate cancer	9.55e-05	0.000353	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—prostate cancer	9.52e-05	0.000352	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTM1—prostate cancer	9.44e-05	0.000349	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—prostate cancer	9.39e-05	0.000348	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—VAV3—prostate cancer	9.33e-05	0.000345	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—STAT3—prostate cancer	9.28e-05	0.000343	CbGpPWpGaD
Vidarabine—ADA—Metabolism—LPL—prostate cancer	9.27e-05	0.000343	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PRKCQ—prostate cancer	9.24e-05	0.000342	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GNRH1—prostate cancer	9.18e-05	0.00034	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VIP—prostate cancer	9.18e-05	0.00034	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CD—prostate cancer	9.07e-05	0.000335	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ITPR1—prostate cancer	9.05e-05	0.000335	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP1A1—prostate cancer	8.95e-05	0.000331	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LPAR1—prostate cancer	8.89e-05	0.000329	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GRP—prostate cancer	8.89e-05	0.000329	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ERCC2—prostate cancer	8.88e-05	0.000328	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LRP2—prostate cancer	8.8e-05	0.000326	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PLCB2—prostate cancer	8.8e-05	0.000326	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ADRB2—prostate cancer	8.69e-05	0.000322	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CX3CL1—prostate cancer	8.63e-05	0.000319	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—P4HB—prostate cancer	8.63e-05	0.000319	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—IL6—prostate cancer	8.6e-05	0.000318	CbGpPWpGaD
Vidarabine—ADK—Metabolism—NOS3—prostate cancer	8.56e-05	0.000317	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—VAV3—prostate cancer	8.47e-05	0.000314	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HIST1H2BG—prostate cancer	8.47e-05	0.000313	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGFR—prostate cancer	8.44e-05	0.000312	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—prostate cancer	8.43e-05	0.000312	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GRB7—prostate cancer	8.4e-05	0.000311	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PDE4D—prostate cancer	8.4e-05	0.000311	CbGpPWpGaD
Vidarabine—ADA—Metabolism—MTHFR—prostate cancer	8.34e-05	0.000309	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ITPR1—prostate cancer	8.22e-05	0.000304	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPARA—prostate cancer	8.19e-05	0.000303	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HIST1H4H—prostate cancer	8.18e-05	0.000303	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCL8—prostate cancer	8.18e-05	0.000303	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GNG5—prostate cancer	7.99e-05	0.000296	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KRAS—prostate cancer	7.97e-05	0.000295	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CB—prostate cancer	7.9e-05	0.000292	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTGS2—prostate cancer	7.83e-05	0.00029	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—prostate cancer	7.78e-05	0.000288	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CAV1—prostate cancer	7.7e-05	0.000285	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CA—prostate cancer	7.32e-05	0.000271	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CG—prostate cancer	7.01e-05	0.000259	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTHLH—prostate cancer	6.96e-05	0.000257	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFBR1—prostate cancer	6.96e-05	0.000257	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKR1C3—prostate cancer	6.85e-05	0.000253	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTEN—prostate cancer	6.83e-05	0.000253	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PRKACB—prostate cancer	6.81e-05	0.000252	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—THBS1—prostate cancer	6.64e-05	0.000246	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PPP3CA—prostate cancer	6.64e-05	0.000246	CbGpPWpGaD
Vidarabine—ADA—Metabolism—INS—prostate cancer	6.64e-05	0.000246	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ANXA1—prostate cancer	6.54e-05	0.000242	CbGpPWpGaD
Vidarabine—ADK—Metabolism—EP300—prostate cancer	6.51e-05	0.000241	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CREBBP—prostate cancer	6.5e-05	0.00024	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6—prostate cancer	6.48e-05	0.00024	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PRKCZ—prostate cancer	6.42e-05	0.000238	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CG—prostate cancer	6.28e-05	0.000232	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGFR4—prostate cancer	6.2e-05	0.000229	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PARP1—prostate cancer	6.2e-05	0.000229	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CD—prostate cancer	6.16e-05	0.000228	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CALCA—prostate cancer	6.13e-05	0.000227	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL12—prostate cancer	5.98e-05	0.000221	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKT1—prostate cancer	5.98e-05	0.000221	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NOS3—prostate cancer	5.82e-05	0.000215	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CG—prostate cancer	5.7e-05	0.000211	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CASP9—prostate cancer	5.63e-05	0.000208	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CD—prostate cancer	5.52e-05	0.000204	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PRKCQ—prostate cancer	5.46e-05	0.000202	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NGFR—prostate cancer	5.46e-05	0.000202	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAP3K7—prostate cancer	5.4e-05	0.0002	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CB—prostate cancer	5.37e-05	0.000199	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS2—prostate cancer	5.32e-05	0.000197	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGF10—prostate cancer	5.19e-05	0.000192	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADRB2—prostate cancer	5.13e-05	0.00019	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—JAK2—prostate cancer	5.06e-05	0.000187	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MAP2K1—prostate cancer	5.04e-05	0.000187	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CD—prostate cancer	5.01e-05	0.000185	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VAV3—prostate cancer	5.01e-05	0.000185	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFBR2—prostate cancer	4.93e-05	0.000183	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ITPR1—prostate cancer	4.86e-05	0.00018	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CA—prostate cancer	4.82e-05	0.000178	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CB—prostate cancer	4.81e-05	0.000178	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1R—prostate cancer	4.64e-05	0.000172	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTEN—prostate cancer	4.64e-05	0.000172	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL8—prostate cancer	4.62e-05	0.000171	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—JAK2—prostate cancer	4.6e-05	0.00017	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LPL—prostate cancer	4.45e-05	0.000165	CbGpPWpGaD
Vidarabine—ADA—Metabolism—EP300—prostate cancer	4.43e-05	0.000164	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IL2—prostate cancer	4.42e-05	0.000163	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PDGFRB—prostate cancer	4.41e-05	0.000163	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CB—prostate cancer	4.37e-05	0.000162	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ITGB3—prostate cancer	4.3e-05	0.000159	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL8—prostate cancer	4.2e-05	0.000155	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB3—prostate cancer	4.17e-05	0.000154	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGFR2—prostate cancer	4.16e-05	0.000154	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL2—prostate cancer	4.01e-05	0.000148	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TERT—prostate cancer	4e-05	0.000148	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKT1—prostate cancer	3.94e-05	0.000146	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HIF1A—prostate cancer	3.82e-05	0.000141	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LEP—prostate cancer	3.73e-05	0.000138	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CAV1—prostate cancer	3.7e-05	0.000137	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KDR—prostate cancer	3.66e-05	0.000135	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ESR1—prostate cancer	3.56e-05	0.000132	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—BAD—prostate cancer	3.48e-05	0.000129	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CG—prostate cancer	3.37e-05	0.000125	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APC—prostate cancer	3.37e-05	0.000125	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGF—prostate cancer	3.33e-05	0.000123	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IRS1—prostate cancer	3.33e-05	0.000123	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CA—prostate cancer	3.27e-05	0.000121	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GSK3B—prostate cancer	3.23e-05	0.00012	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—INS—prostate cancer	3.19e-05	0.000118	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CREBBP—prostate cancer	3.12e-05	0.000115	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1—prostate cancer	3.08e-05	0.000114	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EGFR—prostate cancer	3.07e-05	0.000113	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MAP2K1—prostate cancer	2.98e-05	0.00011	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CD—prostate cancer	2.96e-05	0.00011	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CA—prostate cancer	2.93e-05	0.000108	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SERPINE1—prostate cancer	2.93e-05	0.000108	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—KRAS—prostate cancer	2.9e-05	0.000107	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGF2—prostate cancer	2.83e-05	0.000105	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOS3—prostate cancer	2.79e-05	0.000103	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—JAK2—prostate cancer	2.72e-05	0.000101	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKT1—prostate cancer	2.68e-05	9.9e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CA—prostate cancer	2.66e-05	9.85e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MDM2—prostate cancer	2.65e-05	9.81e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB2—prostate cancer	2.61e-05	9.67e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CB—prostate cancer	2.58e-05	9.55e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL8—prostate cancer	2.48e-05	9.17e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1B—prostate cancer	2.42e-05	8.96e-05	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT1—prostate cancer	2.4e-05	8.86e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CASP3—prostate cancer	2.37e-05	8.78e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL2—prostate cancer	2.37e-05	8.77e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6—prostate cancer	2.36e-05	8.72e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCND1—prostate cancer	2.31e-05	8.55e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CTNNB1—prostate cancer	2.29e-05	8.46e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP9—prostate cancer	2.24e-05	8.3e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1A—prostate cancer	2.23e-05	8.27e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTEN—prostate cancer	2.23e-05	8.25e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT1—prostate cancer	2.17e-05	8.05e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EP300—prostate cancer	2.13e-05	7.87e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SRC—prostate cancer	2.07e-05	7.65e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—prostate cancer	2.01e-05	7.45e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STAT3—prostate cancer	1.99e-05	7.38e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MYC—prostate cancer	1.85e-05	6.85e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFB1—prostate cancer	1.85e-05	6.84e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGFR—prostate cancer	1.81e-05	6.7e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KRAS—prostate cancer	1.71e-05	6.33e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CA—prostate cancer	1.57e-05	5.82e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—prostate cancer	1.52e-05	5.63e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6—prostate cancer	1.39e-05	5.15e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT1—prostate cancer	1.28e-05	4.75e-05	CbGpPWpGaD
